Advarra, provider of institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services in North America, announced the acquisition of Quorum, one of the central IRBs in the U.S. and Canada. The transaction also includes Quorum’s research and technology consulting division, Kinetiq.
Read the full release here.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.